Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $38,928.75 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 875 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $44.49, for a total value of $38,928.75. Following the sale, the director directly owned 3,595,011 shares in the company, valued at $159,942,039.39. This trade represents a 0.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Sionna Therapeutics Stock Down 4.2%

Shares of SION opened at $42.37 on Monday. The company has a market capitalization of $1.89 billion and a price-to-earnings ratio of -8.70. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $45.00. The stock has a 50 day moving average price of $38.80 and a 200 day moving average price of $27.42.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Analyst Ratings Changes

A number of analysts have recently commented on the company. BTIG Research began coverage on Sionna Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $50.00 target price on the stock. Jones Trading assumed coverage on Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price target on the stock. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Sionna Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Sionna Therapeutics News Roundup

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Senior insiders and institutional holders still retain very large stakes (reported holdings ~3.596M shares each, valued ~ $160M), which signals continued alignment with long‑term performance and limits the risk of a meaningful shift in control. SEC filing
• Negative Sentiment: Director Peter A. Thompson sold a total of 1,875 SION shares across Dec. 17–19 at an average price ~ $44.49–44.50 (proceeds ≈ $83.4k). Each sale is small relative to his stake (ownership dipped ~0.03%), but the filings can prompt negative short‑term sentiment. SEC filing
• Negative Sentiment: OrbiMed Advisors LLC (reported as a director-level holder) executed the same pattern of sales (875, 100 and 900 shares on Dec. 17–19) at similar prices, reducing its position by ~0.02–0.03%. Like the individual sales, the absolute size is small versus the owner’s remaining stake but likely contributes to today’s downside pressure. SEC filing

Institutional Trading of Sionna Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics in the 3rd quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $45,000. Virtus Investment Advisers LLC purchased a new position in Sionna Therapeutics in the 2nd quarter valued at $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Sionna Therapeutics in the 2nd quarter valued at $117,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.